Crémieux
Crémieux
ADA-1,06 %
Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
Gallery 1
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Egan Peltan
Egan Peltan
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@AnnieTyzak Eye issues? Never supported with strong evidence.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
Provenance :twitter
8,18 k
0
Le contenu de cette page est fourni par des tiers. Sauf indication contraire, OKX n’est pas l’auteur du ou des articles cités et ne revendique aucun droit d’auteur sur le contenu. Le contenu est fourni à titre d’information uniquement et ne représente pas les opinions d’OKX. Il ne s’agit pas d’une approbation de quelque nature que ce soit et ne doit pas être considéré comme un conseil en investissement ou une sollicitation d’achat ou de vente d’actifs numériques. Dans la mesure où l’IA générative est utilisée pour fournir des résumés ou d’autres informations, ce contenu généré par IA peut être inexact ou incohérent. Veuillez lire l’article associé pour obtenir davantage de détails et d’informations. OKX n’est pas responsable du contenu hébergé sur des sites tiers. La détention d’actifs numériques, y compris les stablecoins et les NFT, implique un niveau de risque élevé et leur valeur peut considérablement fluctuer. Examinez soigneusement votre situation financière pour déterminer si le trading ou la détention d’actifs numériques vous convient.